|Bid||0.0400 x 0|
|Ask||0.0450 x 0|
|Day's Range||0.0400 - 0.0450|
|52 Week Range||0.0300 - 0.1300|
|Beta (5Y Monthly)||-12.08|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb. 28, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Lattice Biologics Ltd. (TSX-V: LBL) (OTCBB: LBLTF) ("Lattice" or the "Company"), an emerging leader in psilocybin research and cannabis company, today announced the formation of its Strategic Advisory Board, a group of respected business leaders that will provide guidance to Lattice’s executive team as it continues to build and strengthen the Company's portfolio of cannabis and psilocybin related brands and products
Lattice Biologics Ltd. (TSX-V: LBL) (OTCBB: LBLTF) ("Lattice" or the "Company"), an emerging leader in psilocybin research and cannabis company, today announced it has entered into a Strategic Supply Agreement (the "Agreement") with Firehouse LLC ("Firehouse"), one of Montana’s most established medical cannabis producers.
Lattice Biologics Ltd. (TSX-V: LBL) (OTCBB: LBLTF) ("Lattice Biologics" or the "Company") announced today that the Company will change its business strategy to focus on the fast growing psychedelics and cannabis markets through the creation of a new life sciences subsidiary. The Company will focus on the research and commercialization of psychedelic products in combination with its stem cell based regenerative compounds while leveraging the Company’s distribution expertise.